Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics
Allan Lipton(National Cancer Centre Japan), Ada Braun(National Cancer Centre Japan), Alison Stopeck(National Cancer Centre Japan), Gary Richardson(Cabrini Hospital), Denise A. Yardley(Sarah Cannon), Kefei Zhou(University of California, Los Angeles), Arun Balakumaran(Allogene Therapeutics (United States)), Karim Fizazi(Université de Lille), Janet E. Brown(University of Sheffield), Neal D. Shore(Carolina Urologic Research Center), Mitchell R. Smith, Miguel Martín(Hospital General Universitario Gregorio Marañón), David H. Henry(Pennsylvania Hospital), Fred Saad(Centre Hospitalier de l’Université de Montréal), Saroj Vadhan‐Raj(The University of Texas MD Anderson Cancer Center)
Cited by 114
Related Papers
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k
Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
|Journal of Clinical Oncology|2010|1.6k